Entity

Time filter

Source Type


Johansson P.,University of Duisburg - Essen | Bergmann A.,University of Kiel | Rahmann S.,University of Duisburg - Essen | Wohlers I.,University of Duisburg - Essen | And 11 more authors.
International Journal of Cancer | Year: 2016

The pathogenesis of T-cell large granular lymphocytic leukemia (T-LGL) is poorly understood, as STAT3 mutations are the only known frequent genetic lesions. Here, we identified non-synonymous alterations in the TNFAIP3 tumor suppressor gene in 3 of 39 T-LGL. In two cases these were somatic mutations, in one case the somatic origin was likely. A further case harbored a SNP that is a known risk allele for autoimmune diseases and B cell lymphomas. Thus, TNFAIP3 mutations represent recurrent genetic lesions in T-LGL that affect about 8% of cases, likely contributing to deregulated NF-κB activity in this leukemia. What's New? T-cell large granular lymphocytic leukemia (T-LGL) is often associated with mutations in the STAT3 gene, but associations with other genetic mutations remain unknown. Here the authors identified non-synonymous mutations in the gene encoding TNF-alpha-induced protein 3 (TNFAIP3), a negative regulator of NF-kappa B signaling, in three patients with T-LGL. The study underscores the important role of NF-kappa B activity in this otherwise poorly understood lymphoid malignancy. © 2015 UICC.


Malli T.,Laboratory for Molecular Biology and Tumor Cytogenetics | Buxhofer-Ausch V.,Hospital Elisabethinen | Rammer M.,Laboratory for Molecular Biology and Tumor Cytogenetics | Erdel M.,Laboratory for Molecular Biology and Tumor Cytogenetics | And 10 more authors.
Genes Chromosomes and Cancer | Year: 2016

Myeloid and lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) abnormalities, also known as 8p11 myeloproliferative syndrome (EMS), represent rare and aggressive disorders, associated with chromosomal aberrations that lead to the fusion of FGFR1 to different partner genes. We report on a third patient with a fusion of the translocated promoter region (TPR) gene, a component of the nuclear pore complex, to FGFR1 due to a novel ins(1;8)(q25;p11p23). The fact that this fusion is a rare but recurrent event in EMS prompted us to examine the localization and transforming potential of the chimeric protein. TPR-FGFR1 localizes in the cytoplasm, although the nuclear pore localization signal of TPR is retained in the fusion protein. Furthermore, TPR-FGFR1 enables cytokine-independent survival, proliferation, and granulocytic differentiation of the interleukin-3 dependent myeloid progenitor cell line 32Dcl3, reflecting the chronic phase of EMS characterized by myeloid hyperplasia. 32Dcl3 cells transformed with the TPR-FGFR1 fusion and treated with increasing concentrations of the tyrosine kinase inhibitors ponatinib (AP24534) and infigratinib (NVP-BGJ398) displayed reduced survival and proliferation with IC50 values of 49.8 and 7.7 nM, respectively. Ponatinib, a multitargeted tyrosine kinase inhibitor, is already shown to be effective against several FGFR1-fusion kinases. Infigratinib, tested only against FGFR1OP2-FGFR1 to date, is also efficient against TPR-FGFR1. Taking its high specificity for FGFRs into account, infigratinib could be beneficial for EMS patients and should be further investigated for the treatment of myeloproliferative neoplasms with FGFR1 abnormalities. © 2015 Wiley Periodicals, Inc.


Malli T.,Laboratory for Molecular Biology and Tumor Cytogenetics | Duba H..-C.,General Womens and Childrens Hospital | Erdel M.,Laboratory for Molecular Biology and Tumor Cytogenetics | Marschon R.,Laboratory for Molecular Biology and Tumor Cytogenetics | And 7 more authors.
American Journal of Medical Genetics, Part A | Year: 2014

Here, we report on a male patient with developmental delay, speech impairment, mild dysmorphic features, and borderline intellectual disability, bearing a de novo balanced t(5;6)(q11;q25.3). By combining FISH and long distance inverse PCR, we identified two genes, ADAMTS6 and ARID1B, which were disrupted at the translocation breakpoints. Due to the opposing transcriptional directions of the two genes, no fusion transcripts could be formed. ADAMTS6 on chromosome 5 encodes a zinc metalloprotease. To date, there has been no information about the substrates and the exact role of this enzyme protein. ARID1B on chromosome 6 is involved in chromatin remodeling and transcriptional activation and is known to play a role in neural development. To our knowledge, this is the fourth translocation involving ARID1B reported in association with intellectual disability. ARID1B haploinsufficiency has already been described in patients with intellectual disabilities with or without corpus callosum abnormalities, Coffin-Siris syndrome and autism (OMIM 614562 and OMIM 614556). A review of patients with ARID1B mutations reveals their broad phenotypic variability. The phenotype of the present patient is of the mildest described to date and further underscores this observation. We conclude that the most prominent and consistent clinical findings in patients with ARID1B haploinsufficiency are developmental delay, speech impairment and intellectual disability and propose that patients with unresolved genetic background and these clinical findings should be considered for ARID1B mutation screening. © 2014 Wiley Periodicals, Inc.

Discover hidden collaborations